Exponent Expands Capabilities in Pharmacoepidemiology and Regulatory Sciences During Global Health Crisis
Exponent is pleased to announce that Dr. Sheila Weiss, Dr. David Dore, and Dr. Joshua Gagne have joined the Health Sciences practice under the leadership of Dr. Fionna Mowat, Corporate Vice President and Director of the Health Sciences practice.
These three principal scientists bring world-class pharmacoepidemiology expertise to Exponent’s work on drugs, devices, and other FDA-regulated medical products from pre-approval through post-marketing. Teaming with engineers, materials scientists, data scientists, and human factors experts, the Health Sciences pharmacoepidemiology team brings innovation and novel approaches to complex issues in the analyses of electronic medical or health records (EMR/EHR) and regulatory strategies.
“The COVID-19 crisis has put our societies' interconnected health and well-being at the forefront of many global debates. Exponent is strengthening our team to accurately and objectively study and measure these connections and the efficacy of our collective responses,” said Dr. Mowat. “Sheila, David, and Joshua possess the combined research, regulatory, and business acumen to support our clients around the globe, as the pharmaceutical industry is on the precipice of several developments with the potential to vastly improve global health and safety.”
Exponent's Health Sciences practice applies unparalleled, interdisciplinary expertise to evaluate the full range of environmental, occupational, and public health issues that face our nation and the world. These issues include potential health effects associated with environmental agents, chemicals, consumer products, food, and pharmaceutical products.